key: cord-0704085-3n3vqyw6
authors: Perillat, Lucie; Baigrie, Brian S.
title: COVID‐19 and the generation of novel scientific knowledge: Research questions and study designs
date: 2021-02-15
journal: J Eval Clin Pract
DOI: 10.1111/jep.13550
sha: c007524de09d5cf029a267046c1cd783c3512259
doc_id: 704085
cord_uid: 3n3vqyw6

RATIONALE, AIMS, AND OBJECTIVES: One of the sectors challenged by the COVID‐19 pandemic is medical research. COVID‐19 originates from a novel coronavirus (SARS‐CoV‐2) and the scientific community is faced with the daunting task of creating a novel model for this pandemic or, in other words, creating novel science. This paper is the first part of a series of two papers that explore the intricate relationship between the different challenges that have hindered biomedical research and the generation of scientific knowledge during the COVID‐19 pandemic. METHODS: During the early stages of the pandemic, research conducted on hydroxychloroquine (HCQ) was chaotic and sparked several heated debates with respect to the scientific methods used and the quality of knowledge generated. Research on HCQ is used as a case study in both papers. The authors explored biomedical databases, peer‐reviewed journals, pre‐print servers, and media articles to identify relevant literature on HCQ and COVID‐19, and examined philosophical perspectives on medical research in the context of this pandemic and previous global health challenges. RESULTS: This paper demonstrates that a lack of prioritization among research questions and therapeutics was responsible for the duplication of clinical trials and the dispersion of precious resources. Study designs, aimed at minimising biases and increasing objectivity, were, instead, the subject of fruitless oppositions. The duplication of research works, combined with poor‐quality research, has greatly contributed to slowing down the creation of novel scientific knowledge. CONCLUSIONS: The COVID‐19 pandemic presented challenges in terms of (1) finding and prioritising relevant research questions and (2) choosing study designs that are appropriate for a time of emergency.

of creating a novel model for the COVID-19 pandemic or, in other words, creating novel science (ie, knowledge that is unexpected in light of received scientific opinion). * Since January 2020, researchers have attempted to uncover the origin of the virus and its mechanism of replication and have rapidly developed diagnostic tools and a number of vaccine candidates that are still under review.

Building on the experiences of past epidemics-specifically, the 2014-2016 Ebola outbreak-the WHO identified research as an ethical imperative † and an essential part of the response to health emergencies. 5, 6 Research is equally essential for generating a knowledge base about the present pandemic, as well as future global health challenges. This newfound consciousness for what is now characterized as "epidemic preparedness" can be traced back to the 2003 SARS outbreak. The last Ebola epidemic represented a turning point in epidemic preparedness efforts: following this outbreak, the pace at which policymakers and academics developed tools to address the next health emergency increased exponentially. 7 The creation of the term 'Disease X', representing the threat of a pandemic caused by a currently unknown pathogen, as well as the development of initiatives, such as the WHO R&D Blueprint 8 and the Coalition for Epidemic Preparedness Innovations (CEPI), are evidence that there has, indeed, been a shift in consciousness. While the COVID-19 pandemic response has evidently been informed and shaped by these interepidemic efforts, generating valuable scientific knowledge during an emergency remains a challenge. In this context, one candidate drug, hydroxychloroquine (HCQ), sparked particular interest among members of the scientific community and will serve as a case study for this paper. HCQ is an antimalarial drug, whose toxicity profile is wellknown for approved conditions, such as rheumatoid arthritis and systemic lupus erythematosus. It was thought that HCQ could inhibit the pH-dependent steps of SARS-CoV-2 replication. 9 So far, and especially during the early stages of the pandemic, research conducted on this drug was chaotic and sparked several heated debates with respect to the scientific methods used and the quality of knowledge generated.

In the context of uncertainty and urgency associated with the COVID-19 pandemic, two strategies, which Angus 10 calls "exploitation" and "exploration", seem to be in tension with one another. ‡ According to Angus, "exploitation refers to acting on current knowledge, habits, or beliefs despite uncertainty. This is the 'just do it' option: give various therapies (eg, chloroquine) to affected patients based on current knowledge or a hunch. Exploration refers to actions taken to generate new knowledge and reduce uncertainty, for example, testing therapies in an RCT. This is the 'must learn' option. Currently, these approaches are framed as a choice: do something (treat the patient) or learn something (test the drug)." 10(p.1895) In other words, some prefer to take action quickly despite uncertainty, while others choose to wait for robust evidence before taking any action.

The effort to find the right balance between the two underlies most of the challenges that have hindered medical research. Different authors have started to identify some of these challenges, such as patient inclusion in clinical trials, 11 data sharing, 12 publication ethics, 13 and research waste. 14 These articles, which tend to be short columns or editorials, typically focus on very specific issues. However, since these challenges tend to compound each other, it is also enlightening to look at them from a broader perspective and examine their intricate relationships.

In the context of COVID-19 and medical research, the question at hand is the generation of a valuable and actionable body of novel scientific knowledge in a relatively short timeframe. The literature suggests that a set of specific issues often complicate the generation of knowledge, regardless of whether research is conducted in a time of emergency or not. These issues are:

1. Inappropriate research questions and study designs. Chalmers and Glasziou 15 argue that "choosing the wrong questions for research" 15(p.86) and "doing studies that are unnecessary, or poorly designed" 15(p.87) result in research waste (ie, scientific knowledge that does not have practical value or is not translated into practice). While undoubtedly there are several ways to examine this issue, this paper will take the position that at least four elements are needed to generate valuable scientific knowledge: (1) relevant research questions, (2) adequate and rigorous study designs, and appropriate ways to (3) evaluate, and (4) report newly acquired knowledge. This first part of a larger study will examine challenges presented by the COVID-19 pandemic in terms of the first two elements. A follow-up paper will turn to the third and fourth elements.

Ensuring that research questions are relevant to the COVID-19 response is the first step in the generation of valuable knowledge.

Without relevant research questions (including the identification of appropriate populations, interventions and outcomes), actionable findings cannot be generated. The difficulty lies in that it is often difficult to identify a clear, testable and relevant hypothesis at the beginning of an outbreak, when information about the pathogen is scarce and fleeting. 17 Prioritising relevant research questions during a pandemic is crucial and can be justified on ethical and practical considerations. (1) scientific and social value, (2) respect for persons, (3) community engagement, (4) concern for participant welfare and interests, (5) favourable risk-benefit balance, (6) justice in the distribution of benefits and burdens, (7) post-trial access. ¶ The first principle, which is the one that is most pertinent to this paper, is formulated as follows: "A clinical study's value depends on the quality of the scientific information produced and the relevance of the information to addressing public health or clinical issues"**. 18(p.477) However, the criteria to determine whether a study has more value than another remain unclear. According to the NAM report, the information produced by a trial must justify the risks and the allocation of resources and be of sufficient quality to inform decisions. † †16 A trial must also address "an important clinical question that cannot be rapidly answered by other means". 17 20 and is especially salient during health emergencies. 10 Healthcare workers have continuously been under pressure because of the growing number of COVID-19 patients, the risks of infections, the lack of equipment, and the pre-existing frailties of health care systems. Until research and care become integrated, every trial runs the risk of being a burden for the healthcare system, even more so if the research question is not directly relevant to the pandemic response. Ideally, during a pandemic, funding should be available for external research teams so as to alleviate the clinical staff's workload. 17 During the 2014-2016 Ebola outbreak, researchers investigated a large number of therapeutics for which the evidence available was very limited. The WHO staff, research funding agencies, and ethics boards were overwhelmed by a large number of proposals. As such, the authors of the NAM Report recommended that "in the event of a rapidly progressing outbreak it is critical to create a mechanism to prioritize investigational agents for study and limit the conduct of the clinical trials to a small number of products, focusing on those with the most promising preclinical or human clinical data, in order to maximize the likelihood that meaningful results will be generated." 16(p.46) The lesson from these considerations, then, is that pursuit of irrelevant research questions can be explained by an absence of (1) research prioritization and (2) mechanisms to avoid the duplication of research works. In the next section, this paper will examine whether these two issues have been adequately addressed since the last Ebola outbreak. To address the NAM's recommendation to limit the number of therapeutics investigated, WHO working groups started, as early as January 24, 2020, to work on therapeutics prioritization. 21 These working groups established a dozen criteria-preclinical efficacy in non-human primates, safety profiles from non-clinical studies, and quality of manufacturing as mandatory criteria 22 -and generated a shortlist of around 25 candidate drugs. A few months later, by April 2020, a new list included over 150 therapeutics (or combinations of therapeutics), 23 which appears counter-productive with respect to their first prioritization efforts. Moreover, there is a discrepancy between what has been prioritized-and the evidence behind it-and what is being studied. As of January 16, 2021, 272 of the 2409 trials tested HCQ, whereas only 40 tested Remdesivir. 24 However, the WHO stated in January 2020 that "Remdesivir was considered the most promising candidate based on the broad antiviral spectrum, the in-vitro and in-vivo data available […] and the extensive clinical safety database." 21(p.9) One of the reasons why such a high number of studies were performed on HCQ compared to Remdesivir is the relatively low cost of (and ease of access to) HCQ. On the other hand, carrying out a study on Remdesivir involved making arrangements with Gilead.

The opportunity cost is another essential determinant in defining what research questions are pursued. At first sight, HCQ was a promising candidate therapeutic given its low cost and wide availability.

For the same reason, it was an attractive investigational treatment for researchers.

Redundancy in research works results in the dispersed allocation of scarce resources (studies are competing for hospital infrastructure, staff, funding, and patient base), which slows down the creation of novel scientific knowledge. This challenge is specific to the COVID-19 pandemic since relatively few trials were conducted during past epidemics (none during the 2003 SARS outbreak, 17 18 during the 2014-2016 Ebola epidemic 16 ). Patient enrolment is challenging during a health emergency and, by limiting the number of trials, as suggested in the NAM report, the chances of enroling enough patients and reaching definite conclusions are maximized. 16 By the time a trial starts, the number of patients admitted to the ICU has largely decreased (due to the implementation of non-pharmaceutical interventions), making it difficult to reach a pre-specified sample size. 11 Part of the difficulty is that obtaining ethics approval takes time. During the 2003 SARS outbreak in Toronto, the 18-day delay between the official beginning of the outbreak, and the ethics approval of the first clinical trial (which, ultimately, was not conducted), resulted in a loss of 60% of patients who could have been enroled. 17 To address this issue, international organizations, 5,25 as well as scholars, 26,27 developed a system of expedited ethics reviews.*** In the context of COVID-19, the issue is compounded by the difficulties of approving and implementing multi-site protocols, given the differences in national resources and healthcare systems. This has posed numerous challenges to the rapid launching of multi-site trials, such as SOLIDARITY and DISCOVERY (the French-led arm of SOLIDAR-ITY). 28 By overwhelming ethics committees and regulatory bodies, the duplication of trials has exacerbated the difficulties associated with red tape that is often excessive.

Mechanisms to limit the number of trials allowed to proceed have not been established since the last Ebola outbreak. While it was reasonable, at the beginning of the pandemic, to expect that HCQ would be tested as a cure, prophylaxis and in combination with other therapeutics, such a high number of studies (272) was not justified. Ideally, trial registration should provide information on what trials are in progress and de-incentivize duplication. However, this rarely happens in practice, especially considering the strong academic and financial incentives that have been in place since the beginning of the outbreak.

There is no legal basis for an international body to examine all trial proposals and determine which trials are allowed to proceed. The R&D Blueprint acknowledges this issue, stating that to avoid "unnecessary duplication […] appropriate incentives and other measures" can be implemented 8(p.11) . However, there is no additional information on what those incentives might be. A few platforms, such as the Trial Innovation Network, SMART IRB or the COVID19 CP, aim to create incentives and facilitators for collaboration at the clinical level. SMART IRB describes itself as: "a platform designed to ease common challenges associated with initiating multi-site research." 29 The other two platforms expedite approval for proposals that create multi-site collaborations. 30,31 † † † Unfortunately, their lack of exposure, partnering institutions, and resources explains the persistence of this issue.

While the objective should be to minimize duplication of research as much as possible, it is clear that duplication is sometimes desirable, especially when the scientific community wishes to have higher confidence in research findings (through replication of studies). In the context of this pandemic, the duplication of research on vaccines is, for example, both appropriate and desirable, given the need for equitable access to vaccines that are suitable for a range of populations, settings, and storage requirements. 32 However, having different research groups chasing the same irrelevant research question should be avoided.

While lessons learned from the last Ebola outbreak helped researchers prioritize research questions and identify candidate therapeutics, the duplication of research remains a problem. This issue is compounded by a large number of researchers who exclusively want to work on vaccine and drug development. To address these challenges, the priority is to clearly define what a "relevant" research question is and to strengthen coordination efforts. While these two steps are crucial in facilitating the generation of valuable scientific knowledge during health emergencies, it will not be sufficient unless behaviours and mindsets also change. ‡ ‡ ‡

Since the beginning of the pandemic, researchers seem to have embarked on a quest to find a "miracle" study design-but disagree on what that design should be. As such, researchers advocate for what they consider to be the best methodological approach while condemning all others. Past health emergencies have also witnessed several disputes regarding how clinical trials ought to be designed, thereby, further delaying their launching. § § §16 The 2009 H1N1 and the 2014-2016 Ebola outbreaks revealed the need for a portfolio of designs that are best suited to a health emergency. This rise in consciousness incentivized scholars to develop new designs meant to address the various challenges engendered by a pandemic. These initiatives resulted in the development of the SOLIDARITY and REMAP-CAP trials, launched on March 18 and April 9, 2020, respectively. 33, 34 With respect to research conducted on HCQ, the question of study designs sparked lengthy debates across the scientific community, politicians and the public alike. Most parties to this debate acknowledge that the quality of findings generated has been poor. 35, 36 Glasziou, Sanders and Hoffman bemoan "a deluge of poor quality research [that] is sabotaging an effective evidence based response." 14(p.1) While it is outside the scope of this paper to conduct a systematic review of all the studies on HCQ and determine its efficacy, it might prove useful to outline some of the characteristics of these studies, such as the number of participants, the type of study design, the publication format and the study's conclusions and limitations. For the purpose of this paper, studies on the efficacy of HCQ as a treatment (not prophylaxis) published between January and July 17, 2020 were selected (35 studies). By July 17, the general consensus was that HCQ would not be an effective treatment for COVID- 18 report no significant benefit [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] and four report increased risks. [76] [77] [78] [79] 4. Significant number of retracted studies: three studies on HCQ were retracted 50, 78, 80 and another was the subject of a statement of concern from Elsevier and is currently under investigation. 47 5. Large amount of non-peer-reviewed articles: only 15 of these studies were peer-reviewed. 6 . Lack of adverse event reporting: 17 studies did not formally report adverse events, which is, however, one of the major concerns clinicians have when prescribing HCQ. Indeed, HCQ is known to cause renal, hepatic and cardiovascular adverse effects. 9 COVID-19 patients in the ICU are more likely to have co-morbidities (including renal, hepatic and cardiovascular dysfunctions) and be given high doses of HCQ, thereby increasing the risks of adverse events. Starting in July 2020, studies tended to report adverse events more systematically. This paper will now analyse the three major strategies that have been suggested since the beginning of the pandemic (traditional designs, Big Data and REMAP-CAP) to determine if a "miracle" design can, indeed, be found.

A vocal constituency of the scientific community advocates for maintaining the standards and methods generally used outside of health emergencies. 81 Simple designs that have been frequently used in the past are thought to help preserve scientific rigour without the prospect of overwhelming the clinical network. 82 While the first few completed clinical trials on HCQ were received from China, the antimalarial drug was placed under the international spotlight due to two French studies that were published in March 2020. 47, 49 Despite their methodological limitations (see Appendix A), the advertisement made by Raoult (one of the authors of these French studies) and politicians 83 sparked hope and controversy among the population, with the result that another team of researchers decided to replicate the study by performing a prospective case series of 11 patients. However, this study did not yield conclusive findings. 60 This is a typical example where researchers were obligated to replicate knowledge generated instead of building on it, thereby slowing down research efforts. At the time, Raoult claimed that a situation of emergency is a licence to abandon the scientific method and a call to action (ie, population-wide distribution of HCQ). ¶ ¶ ¶84 As such, he agitated against RCTs as being unduly time-consuming and contended that including placebos and control groups is unethical. 84 This debate can be traced back to the last Ebola outbreak 86 but seems to have been settled, for the most part, since then.**** Regardless, clinicians might rightfully be torn between attempting to cure patients with what is available and continuing unabated with their research. However, while Raoult referenced the Hippocratic Oath to justify giving HCQ to every patient, regardless of the risks, 84 it seems reasonable to respond to Raoult that this very same Hippocratic Oath ("first do no harm") mandates against imprudent, population-wide prescriptions of investigational drugs. This brings us to reflect on the prescription of off-label drug use. This practice is widespread † † † †87 but 73% of off-label drugs are supported by very poor or no scientific evidence. 88 Prescribing off-label drugs can also undermine research efforts since data cannot be collected on patients who are prescribed the investigational treatment. 36 Following these two politicized studies, which polarized public and scientific opinion, it became evident for many that only a RCT would provide definite conclusions regarding the efficacy of HCQ.

However, the preliminary results of the UK RECOVERY trial (an adaptive factorial trial [92] [93] [94] ), released on June 5, 2020, suggested that a RCT is far from bringing all the answers. The DMC stated that the interim results, based on 4674 patients, revealed "no beneficial effects of hydroxychloroquine" and that they had decided to "stop enrolling participants to the hydroxychloroquine arm […] with immediate effect". 95 Nevertheless, researchers were quick to criticize these findings, even though they came from a RCT that, supposedly, ranks high in the evidence hierarchy. ¶ ¶ ¶ ¶ The first concern regarding the trial was related to the unusually high dosage of HCQ. Indeed, patients received 2400 mg of HCQ in the first 24 hours, which is well above the dosage recommended by the FDA on the Emergency Use Authorization (800 mg). 96 While this dosage decision is explained in the protocol on the basis of available data of the IC 50 for SARS-CoV-2 (how much substance in needed in plasma to inhibit the virus by 50%),***** 94 it remains unclear whether this dosage was warranted and did not pose an unreasonable risk to patients. The population of patients selected was also questioned. Some argued that patients who received HCQ in this trial (mainly severely ill patients) would not benefit from receiving the treatment. This is because COVID-19 is a three-stage disease with an initial viral replication phase, followed by a pulmonary phase and then a "cytokine storm" causing tissue damage (when patients are in the ICU). 97 Giving HCQ, an antiviral, would, thus, only be beneficial for patients who were still in the early stages of the disease. This example shows that results from a seemingly well that HCQ was associated with a higher risk of mortality and cardiac arrhythmia. 78 Immediately following this publication, guidelines on the use of HCQ changed dramatically: on May 25, 2020, the WHO suspended all HCQ arms and national trials followed in its path. 99 The French Minister of Health suspended the authorization he had exceptionally issued on the use of HCQ in the clinical setting. 100 The large sample size, which is often-incorrectly-associated with high-quality findings, was used as justification to make these decisions. However, concerns about the study data were quickly raised, first on Twitter, 101 and then in an open letter addressed to The Lancet, which outlined 10 concerns, including discrepancies with government data and inadequate statistical adjustments. 102 Three out of the four authors retracted the study on June 5, 2020, 103 which led the WHO and national policymakers to resume clinical trials. 99 In addition to the negative consequences that these contradicting decisions might have had on clinical trials, this study also contributed to making COVID-19 patients following a HCQ treatment even more concerned about their vital prognosis.

Thus, generating data quickly is not helpful if the data collection methods are inappropriate or if the data only supports limited conclusions, which clearly was the case of the data collected by the COVID-19 4CE Consortium. ‡ ‡ ‡ ‡ ‡104 Using patient-level data, if collected adequately and internationally, would yield more generalizable findings than those that are currently available. Nevertheless, advocating for this approach seems to overlook the numerous challenges that remain to be addressed. First, the question of patient privacy and re-identification is often seen as a significant barrier to the sharing of EHRs. 106 Besides, there are currently no incentives to share clinical data since there is no mechanism for academic recognition and data ownership. § § § § §107-109 Researchers might prefer to wait until they have conclusions to publish rather than share their raw data.

The third approach, advocated by Angus 10 and others, 110, 111 is to choose an adaptive design that is "pre-planned, pre-approved and practiced" 112(p.12) during the inter-epidemic period. Such a design, REMAP-CAP, which stands for Randomized, Embedded (into clinical care), Multifactorial, Adaptive, Platform trial for Community-Acquired Pneumonia (CAP), was developed following the H1N1 outbreak. 113 Following the approval of the core protocol and the pandemic appendix, the trial was launched in 2016 and, as of January 16, 2021, includes 290 sites in 19 countries. 11 Enrolment of COVID-19 patients started soon after the beginning of the pandemic. This design combines elements from a platform trial, upon which multiple research questions can be investigated, and an adaptive trial, which allows for design modifications based on a Bayesian analysis of interim results. [114] [115] [116] [117] [118] We are told that this design addresses a "disease or condition, rather than a particular intervention" 118(p.797) , which can be helpful when investigating emerging pathogens, such as SARS-CoV-2. The different adaptations used in REMAP-CAP are ¶ ¶ ¶ ¶ ¶119 :

• Enrichment: population modifications are made if the treatment proves to be more efficient on a subset of the population.

According to Angus, this allows for a "precision medicine" approach and a better estimation of the intervention's effects on individual patients. 98 • Treatment arms: addition or termination of arms based on interim results and simulations.

• Patient allocation: Response-Adaptive Randomization (RAR) allows participants to become more likely to be enroled in the more promising arm as evidence accumulate.

According to Angus, REMAP trials are most adequate to accommodate the complex web of constraints that a pandemic generates. 114 RAR tends to shorten the time required to generate conclusive findings and to decrease the number of participants needed, 118,120 which minimizes challenges around patient inclusion. By allowing more participants into the more promising arm, RAR might also be a partial response to clinicians' concerns about randomization. 121 The organization of the protocol (core protocol and appendices for each new arm) also facilitates ethics approval. 118 However, these designs also have practical and statistical limitations.****** An adaptive trial requires a tremendous amount of pretrial planning and simulations in order to pre-specify the statistical methods and algorithms used to evaluate interim results. 118 Given the uncertainty associated with any pandemic, one can question how much of the trial can actually be planned ahead of time. RAR, while admittedly more intuitive, can also result in a population drift. 121 Participants know that the later they enter the trial, the more chances they have of being allocated to the more promising arm. As such, patients who enrol later are more likely to be healthier since they can afford to wait. † † † † † † Finally, REMAP-CAP, as any multi-site trial, risks having different "standard of care" practices across sites, due to socio-economic differences. A lack of mechanisms for data harmonization makes it difficult to compare data and generalize results. 104 "Standard of care" guidelines for COVID-19 patients might also change over time, as new evidence arises. 123 While a REMAP design should not be considered flawless, it seems to adequately address some of the challenges imposed by a pandemic, provided, of course, that it is conducted properly. Given the amount of pre-trial planning required before launching an adaptive trial, it must be designed before the onset of an outbreak, which is why REMAP-CAP has an advantage over other adaptive trials. If the results live up to expectations, REMAP-CAP will show that aiming for a personalized approach to medicine and a learning healthcare system is possible, even during a pandemic. 10, 124 However, results and data from the HCQ arm of this trial have yet to be released, ‡ ‡ ‡ ‡ ‡ ‡ making it impossible to assert with certainty that it is the most appropriate design for an emergency. During the inter-epidemic period, the question of which design is preferable has been addressed but discussions have resulted in very few definite answers. In the context of the COVID-19 pandemic, members of the scientific community have widely divergent views on what they consider to be the most appropriate design during health emergencies. 10 Given the above considerations, the inescapable conclusion is that the quest for a single, perfect design is futile. Instead, in order to ensure a better alignment between information clinicians and policymakers need and information that is generated by research, two objectives should be pursued: maintaining scientific rigour while embracing a methodological pluralism stipulating that the value of a plurality of designs is its prospect for the acceleration of the generation of scientific knowledge.

This first paper has demonstrated that the COVID-19 pandemic has presented challenges to the generation of novel scientific knowledge in terms of (1) finding and prioritising relevant research questions and 

In a follow-up paper, we will continue to explore the relationship between the different challenges that have hindered biomedical research and the generation of novel scientific knowledge during the COVID-19 pandemic. In this second paper, we will turn to the challenges presented by the COVID-19 pandemic in terms of (3) evaluating evidence for the purpose of making evidence-based decisions and (4) sharing scientific findings with the rest of the scientific community and the general public. In a time where confusion, uncertainty and fear rule, and where mitigation strategies rely on people's adherence to science-based guidelines, this second paper will demonstrate the importance of communicating scientific findings, and their limitations, in a clear and transparent manner.

We would like to thank Colin Deinhardt at the E. J. Pratt Library for his advice and help in finding COVID-19 databases and relevant sources on COVID-19 and hydroxychloroquine. There was no funding for this study.

The authors declare no conflict of interest. (2020), 1 the WHO repeatedly describes the role of the scientific community as identifying and addressing "knowledge gaps" (see p. 2, 4, 9) . However, the issue extends far beyond filling knowledge gaps. The initial model of the COVID-19 pandemic was primarily based on lessons the scientific community learned from the 2003 SARS epidemic and SARS-CoV (the virus causing SARS). Given the approximate 80% similarity between the genomes of the two viruses 2,3 and the similarities in transmission routes, it was widely assumed that conclusions about SARS-CoV could be extrapolated to SARS-CoV-2. However, Wilder-Smith and colleagues 4 call attention to the fact that these viruses are very different, and assumptions about infectious periods, transmission and severity do not always hold. More than filling knowledge gaps, the scientific community needs to create a new scientific model for COVID-19. † Section 8 (p. 30-34) of the WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks (2016) 5 outlines the appropriate role of research during health emergencies. The central argument of this section is that "there is a moral obligation to learn as much as possible as quickly as possible, in order to inform the ongoing public health response, and to allow for proper scientific evaluation of new interventions being tested." 5(p.30) This WHO document provides guidance on fast-tracking ethics reviews, integrating research and public health responses and selecting appropriate research methods. ‡ Angus 10 locates the source of this tension in the institutional structure of medicine, which is organized in a way that ensures that clinical practice (doing) and clinical research (learning) are separate tasks. Angus contends that there are "huge costs to this division, including delays in knowledge acquisition and dissemination. In normal times, these costs are somewhat suppressed or ignored, but in a crisis such as the COVID-19 pandemic, they come into sharp focus" 10(p.1895) . § The specific examples of the H1N5 outbreak in Indonesia and the 2015 Zika outbreak are described in sect. 4, in the second paper of this series. As for Ebola, the author of the National Academy of Medicine (NAM) report 16 identified data sharing as a central issue during the outbreak. Recommendation 2b states that "Data collection should begin as soon as possible, and data should be shared and coordinated in a central database to advance an understanding of the natural history of the disease and of the best practices for standard of care. This information should also be used to inform protocols for clinical trials." 16(p.10) In the report, the authors argue that the inappropriate prioritization of investigational treatments (ie, interventions and, to an extent, research questions) and the inappropriate choice of study designs also complicated the generation of a robust body of knowledge 16(sect.2) . ¶ These seven principles are outlined on p. 53 to 61 of the NAM report (2017). 16 They were selected by the report committee using the following documents as a framework: Nuremberg Code (1947) ** When summarising the findings of the NAM report, 16 Edwards and Kochhar 18 mention that "the knowledge gained must justify the risks to the subjects and the costs associated with the trials" 18(p.478) . However, how this is to be determined and quantified remains unclear in the article. The importance of the distinction for a theory of evidence between the validity (reliability) of evidence and the relevance (weight) of evidence is argued by Baigrie and Mercuri. 19 † † The "Scientific and Social Value" principle is detailed in sect. 5 it is recommended that there should be greater collaboration between national research governance systems and local research ethics committees. The authors also suggest that the development of advance reviews of generic protocols can help expedite ethics reviews. Tansey and colleagues 26 developed a framework for expedited reviews that rely on proportionality and procedural flexibility. † † † COVID19 CP does not only act as a trial repository but encourages collaboration between trials. However, it primarily focuses on collaboration between RCTs, as opposed to observational and electronic medical records data. 31 As will be argued in sect. 3, in the second paper, there has been a tendency to disproportionately rely on RCTs since the beginning of the COVID-19 pandemic. The COVID19 CP's decision to focus on RCTs is yet another example that is indicative of this tendency. During a health emergency, strengthening collaboration for any research enterprise (and not only randomized controlled trials) is crucial. ‡ ‡ ‡ The authors would like to emphasize that the question at hand here is the regulation and governance of medical research during an emergency. The question of knowing whether policymakers should prioritize mitigation strategies, therapeutics or vaccines (ie, divide resources equally or favour a single strategy) is an important but distinct issue that is best addressed once more hindsight is acquired. Past health emergencies have shown that vaccines are usually developed in a second phase, after research on repurposed drugs and mitigation strategies have been carried out. This is to be expected considering the time that it takes to develop, approve and manufacture a vaccine. Whether the COVID-19 pandemic will result in the modification of research responses to a health emergency remains to be seen. § § § Sect. 2 (p. of the NAM report (2017) 16 examines the question of choosing appropriate trial designs during a health emergency. During the 2014-2016 Ebola outbreak, stakeholders agreed that "too much time was spent debating trial design, rather than quickly implementing trials and discovering safe and effective products in time to fight the epidemic" 16(p.47) . Both randomized and non-randomized trials were discussed at the time and in the report. Since ethical and logistical concerns were raised regarding randomization, single-arm studies with historical controls were discussed as an alternative. However, the authors of the NAM report ultimately conclude that: "Randomized controlled trials are the most reliable way to identify the relative benefits and risks of investigational products, and, except when the rare circumstances detailed in Box 2-5 are applicable, every effort should be made to implement them during epidemics." 16(p.75) ¶ ¶ ¶ Raoult, in an open letter to a French newspaper, described the scientific method as a "moral dictatorship" and methodologists as "methodology freaks". 84 He insisted that "we must get rid of mathematicians [whom he earlier described as methodologists], [who are] meteorologists in this area." In his letter, he relied on the parachute paradigm 85 to condemn the conduct of RCTs during health emergencies, arguing that the use of placebos and control groups is not ethical in such situations. Meyer, in a response published in the same newspaper, argued that the parachute paradigm does not hold in the case of HCQ: "this example is not valid: the statistical method is only used when there is obvious uncertainty about the answer, and not when the laws of physics are sufficient to predict the result with a negligible margin of error." 82 [authors' translation].

**** Concerns about randomization, control groups, and placebos are frequently raised during health emergencies. The NAM report mentions that such a controversy occurred during the 2014-2016 Ebola outbreak: some argued that "communities would not accept a randomized controlled trial because it would 'deny a new experimental treatment to some participants'" 16(p.51) . Others stated that "trials 'should not include a placebo: exposed and vulnerable people in Ebola-affected and low-resource settings should not be led to think they are either being treated or protected when they are not'". 16(p.65) Others, yet, argued that randomization, controls and placebos "would be acceptable to the community if public health leaders were 'to articulate the rationale for conducting scientifically valid trials, to work closely with local health authorities, and to engage community leaders'" 16(p.51) . In light of these conflicting views, the authors determined that RCTs were ethical and that "[the above] considerations do not warrant the a priori rejection of the use of a placebo but rather should be taken into consideration within the specific context of a trial." 16(p.65) The 2016 WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks seems to agree with this conclusion, recommending that: "In clinical trials, the appropriateness of features such as randomization, placebo controls, blinding or masking should be determined on a caseby-case basis, with attention to both the scientific validity of the data and the acceptability of the methodology to the community from which participants will be drawn." 5(p.33) † † † † Wittich and colleagues 87 note that prescriptions of off-label drugs represent 21% of all prescriptions in the US and 36.2% of all ICU prescriptions. Despite the fact that this practice is widespread, a study conducted by Cummings showed that two-thirds of patients advocate for the banishment of off-label drug use. 89 ‡ ‡ ‡ ‡ Kalil argues that "in addition to the risk of harming patients without the possibility to even detect the magnitude of harm, the administration of off-label drug use, compassionate drug use, and uncontrolled studies during a pandemic also could discourage patients and clinicians from participating in RCTs, hampering any knowledge that could be gained about the effects of the drug being tested" 90(p.E2) . When an investigational drug is prescribed under an off-label or compassionate use, adverse events are rarely reported in a systematic manner to the scientific community and knowledge about the efficacy or potential harms of said investigational treatment cannot be generated. § § § § These seven principles were summarized and adapted from sect. 9 (p. 35-37) of the WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks (2016). 5 ¶ ¶ ¶ ¶ These critiques of the RECOVERY trial raise the question of whether a negative trial (ie, one that reveals no benefit of the intervention) can ever produce findings that are considered conclusive. Critics can bring into question many aspects of a clinical trial (eg, patient population, dosage regimen, clinical outcomes), as was the case with trials of HCQ. While the question of falsifiability in clinical medicine is interesting, it is beyond the scope of this paper. ***** This decision is explained as follows in the RECOVERY protocol: "the loading dose in RECOVERY is twice the normal dose for treating malaria. However, this dose has been selected based on the available data of the IC 50 for SARS-CoV-2. The objective is to reach plasma concentrations that are inhibitory to the virus as soon as safely possible. The plasma concentrations that will result are at the higher end of those encountered during steady state treatment of rheumatoid arthritis. Given the significant mortality in patients hospitalized with COVID-19, this dose is felt to be justified." 94(p.22-23) † † † † † In the case of RECOVERY, the research findings may, at best, be generalizable to a population of severely ill patients. However, given the three-stage nature of COVID-19, HCQ should be tested in a population of patients who are still in the early stages of the disease (viral phase). Therefore, the results of RECOVERY are not generalizable to the population that would be the target of a HCQ treatment (ie, patients who are still in the viral phase). ‡ ‡ ‡ ‡ ‡ The 4CE Consortium is a grouping of 96 international hospitals that gathered and analysed Electronic Health Records data (using the i2b2 and OMOP platforms) to "inform doctors, epidemiologists and the public about COVID-19 patients with data acquired through the health care process." 105 The report cited here analyses aggregate data from 27 927 COVID-19 patients. The authors "deliberately aggregated the data to expedite the institutional review board (IRB) process at each institution […] . This thereby constrained [their] analyses to count, rather than patient-level, data." 104(p.13) The authors acknowledge this limitation as well as the limited amount of diagnosis code data available and issues with data harmonization across sites. They state that "the limits of [their] data collection method, where [the] results are not tied to the patient level and can be associated across populations, highlights the need for caution with any conclusion […] ." 104(p.13) § § § § § The lack of academic recognition when sharing clinical data is made explicit in the report by Abramowitz and colleagues (2018). 107 The authors mention that researchers "are reticent to hand over data for publication without recognition.

[…] One problem impeding this recognition was that the names of those people who have laboured to produce data are not visible to their users." 107(p.65) . Section V(F) "Key barriers and facilitators to data sharing" of this document further develop this argument. In the WHO consultation on Data and Results Sharing During Public Health Emergencies (2015), 108 sects. 1.4 and 1.5 examine the issue of recognition and data ownership. The authors and interviewees suggest that a "cultural" change in "academic reward structures" 108(p.19) is needed. However, how this should be implemented in practice remains unclear. ¶ ¶ ¶ ¶ ¶ Adaptive Designs for Clinical Trials of Drugs and Biologics FDA Guidance for Industry (2019) 119 provides guidance on how adaptive trials ought to be designed and conducted. It is important to note, however, that "there is [currently] no explicit and transparent review process for APTs [adaptive platform trials], and therefore no mechanism for standardized evaluation across different national and international oversight and review bodies." 118(p.801) Section 5 of this FDA document outlines all the adaptions that can be added to an adaptive platform trial (adaptations to sample size, patient population, treatment arm selection, patient allocation, endpoint selection).

****** Goozner 122 and others 120 note that making modifications based on an interim analysis of the data increases the probability of Type I errors (or false positives). † † † † † † This problem may arise, depending on how the trial is designed and what inclusion criteria are used. Das and Lo carried an analysis of the I-SPY 2 TRIAL (an adaptive platform breast cancer trial) and emphasize that population drift could have been a concern and a limitation in the trial. 120(p.170) ‡ ‡ ‡ ‡ ‡ ‡ Results for the corticosteroid arm of the REMAP-CAP trial were published in JAMA on September 2, 2020. 126 This treatment arm was halted after results from other trials were published. Primary results for the HCQ arm should be released in December 2021, and full study results should be published in June 2022. 127 § § § § § § In the video, Peter Horby (RECOVERY trial co-chair) articulates the three main goals of the RECOVERY trial: (1) to generate the best evidence as fast as possible, (2) to protect patients, (3) to protect the healthcare system so that the staff is not overburdened with too much administrative duties. 125 

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Lucie Perillat https://orcid.org/0000-0002-5124-8570

WHO R&D Blue Print

Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Can we contain the COVID-19 outbreak with the same measures as for SARS?

Guidance for Managing Ethical Issues in Infectious Disease Outbreaks

Research as a part of public health emergency response

A new twenty-first century science for effective epidemic response

An R&D Blueprint for Action to Prevent Epidemics: Plan of Action

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

Optimizing the trade-off between learning and doing in a pandemic

Pandemic preparedness-REMAP-CAP trial

Data sharing in the era of COVID-19

Publication ethics during public health emergencies such as the COVID-19 pandemic

Waste in covid-19 research

Avoidable waste in the production and reporting of research evidence

National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Global Health, Board on Health Sciences Policy, Committee on Clinical Trials During the 2014-2015 Ebola Outbreak. Integrating Clinical research into epidemic response the Ebola experience

Novel pathogens: lessons learned from SARS

Ethics of conducting Clinical research in an outbreak setting

Relevance, validity, and evidential reasoning in Clinical practice

Clinical research and medical care: towards effective and complete integration

Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection

R&D Blueprint Novel Coronavirus: WHO Working Group-Therapeutics Prioritization for COVID-19

int%2Fdocs% 2Fdefault-source%2Fblue-print%2Fwho-working-group-therapeutic s-prioritization

url?sa=t&rct=j&q=& esrc=s&source=web&cd=&ved=2ahUKEwiz3Ybeh5rtAhUkF1kFHZ4 xA44QFjABegQIBxAC&url=https%3A%2F%2Fwww.who.int%2Fdoc s%2Fdefault-source%2Fblue-print%2Fcovid-classification-of-treatm ent-types-rev.pdf%3Fsfvrsn%3D4993afd6_1%26download%3Dtrue &usg=AOvVaw0rpKbzYt5XmCL4Gj31w0wV

WHO. COVID-19 Living Research Map

Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D

A framework for research ethics review during public emergencies

Pandemic disease, public health, and ethics. The Oxford Handbook of Public Health Ethics

Covid-19: Essai Discovery, point d'étape au 7 mai 2020. science pour la santé

National IRB Reliance Initiative https:// smartirb.org

COVID-19 CP. COVID-19 collaboration platform

Ask an expert: why are there so many COVID-19 vaccines -and is it better to have more? GAVI the Vaccine Alliance

UN health chief announces global "solidarity trial" to jumpstart search for COVID-19 treatment

Led global effort fast tracks testing of COVID-19 therapies

COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19

COVID-19): Hydroxychloroquine

COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine

Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Does adding of hydroxychloroquine to the standard care provide any benefit in reducing the mortality among COVID-19 patients?: A systematic review

Review of current evidence of hydroxychloroquine in pharmacotherapy of COVID-19. medRxiv

Targeted update: safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19

Chloroquine, hydroxychloroquine et COVID-19: évaluation pharmacologique

A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19

Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. med-Rxiv

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Philippe

Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)? medRxiv; 2020

Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

Doxycycline and hydroxychloroquine as treatment for high-riskCOVID-19 patients: experience from case series of 54 patients in long-term care facilities. medRxiv

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv

Early hydroxychloroquine is associated with anincrease of survival in COVID-19 patients: an obser-vational study. Preprints

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France

Treatment response to hydroxychloroquine, lopinavir/ritonavir, and antibiotics for moderate COVID 19: A first report on the pharmacological outcomes from South Korea

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19

Observational study of hydroxychloroquine in hospitalized patients with COVID-19

Association of Treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state

Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial running

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-real-world evidence from a we acknowledge the West Virginia Clinical and translational science institute to provide us access, and training to the TriNETX. medRxiv

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study

Compassionate use of hydroxychloroquine in clinicalpractice for patients with mild to severe COVID-19 ina French university hospital

Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19

Hydroxychloroquinewith or without azithromycin and in-hospital mortalityor discharge in patients hospitalized for COVID-19 infec-tion: a cohort study of 4,642 in-patients in France. medRxiv

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

Effect of hydroxychloroquine in hospitalized patients with Covid-19

Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomizedcontrolled trial

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)

Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial

Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study

RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study

Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?

Against pandemic research exceptionalism

On ne peut pas décider de l'utilité d'un traitement sur une intuition. Le Monde

Le médecin peut et doit réfléchir comme un médecin, et non pas comme un méthodologiste

Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials

Randomised controlled trials for Ebola: practical and ethical issues

Ten common questions (and their answers) about off-label drug use

Off-label prescribing among office-based physicians

Adults Ambivalent about the Risks and Benefits of off-Label Prescription Drug Use

Treating COVID-19 off-label drug use, compassionate use and randomized Clinical Trials during pandemics

Panic prescribing has become omnipresent during the COVID-19 pandemic

Analysis Plan RECOVERY

Definition and derivation of baseline characteristics and outcomes

Randomised evaluation of Covid-19 therapy (recovery)

Statement from the Chief Investigators of the RECOV-ERY Trial on hydroxychloroquine

Hydroxychloroquine fact sheet for health care providers

COVID-19 illness in native and immunosuppressed states

Fusing randomized trials with big data: the key to selflearning health care systems?

World Health Organization resumes coronavirus trial on malaria drug hydroxychloroquine after examining safety concerns

Avis du Haut Conseil à la Santé Publique relatif à l'utilisation de l'hydroxycholoroquine dans le Covid-19

A (Longish) post-publication review of the most recent observational study in COVID19 patients treated with (hydroxy) chloroquine. This is retrospective analysis of an international registry with 96,000 hospitalised patients in 6 continents

Retraction-hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

International Electronic Health Record-Derived COVID-19 Clinical Course Profile: The 4CE Consortium

Consortium for clinical characterization of COVID-19 by EHR

Anonymising and sharing individual patient data

Data sharing in public health emergencies: Anthropological and historical perspectives on data sharing during the 2014-2016 Ebola epidemic and the 2016 yellow fever epidemic

WHO consultation on data and results sharing during public health emergencies. Background briefing

Sharing patient-level real-time COVID-19 data

Creating a framework for conducting randomized clinical trials during disease outbreaks

Critical illness in patients with COVID 19 mounting an effective clinical and research response

REMAP-CAP randomized, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia (REMAP-CAP): Pandemic appendix to the core protocol

The REMAP-CAP trial

The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design

Core protocol

Domain-specific appendix: COVID-19 Antiviral therapy

0+-+01+April+2020_WM.pdf. Accessed

REMAP-CAP appendix to core protocol: statistical analysis appendix

Adaptive platform trials: definition, design, conduct and reporting considerations

Adaptive Designs for Clinical Trials of Drugs and Biologics FDA Guidance for Industry. Silver Spring, MD: FDA

Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program

Are outcome-adaptive allocation trials ethical?

Controversy trails adaptive clinical trials

COVID-19 ethics and research

Modernising epidemic science: enabling patient-centred research during epidemics

RECOVERY trial-Randomised evaluation of COVID-19 therapy

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Additional supporting information may be found online in the Supporting Information section at the end of this article.